Product Description
Trandolapril is an angiotensin converting enzyme (ACE) inhibitor. It works by blocking a substance in the body that causes the blood vessels to tighten. As a result, trandolapril relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart. (Sourced from: https://www.mayoclinic.org/drugs-supplements/trandolapril-oral-route/side-effects/drg-20069242?p=1)
Mechanisms of Action: ACE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Greece | Hungary | India | Indonesia | Ireland | Italy | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: COVID-19|Influenza, Human|Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|COVID-19|Influenza, Human |
2026-02-01 |